Difference between revisions of "Sirolimus (Rapamune)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
m (→Also known as) |
||
| (8 intermediate revisions by 2 users not shown) | |||
| Line 3: | Line 3: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[Autoimmune | + | *[[Aplastic anemia]] |
| + | *[[Autoimmune cytopenia]] | ||
| + | *[[Castleman disease]] | ||
*[[Erdheim-Chester disease]] | *[[Erdheim-Chester disease]] | ||
| − | *[[Hodgkin lymphoma]] | + | |
| + | ==Diseases for which it was used== | ||
| + | *[[Classical Hodgkin lymphoma]] | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code names:''' AY 22989, SILA 9268A, SLM, WY-090217 | + | *'''Code names:''' AY-22989, SILA-9268A, SLM, WY-090217 |
*'''Generic names:''' RAPA, rapamycin | *'''Generic names:''' RAPA, rapamycin | ||
*'''Brand name:''' Rapamune | *'''Brand name:''' Rapamune | ||
| Line 15: | Line 19: | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| − | + | ||
[[Category:mTOR inhibitors]] | [[Category:mTOR inhibitors]] | ||
| − | [[Category:Autoimmune | + | [[Category:Aplastic anemia medications]] |
| + | [[Category:Autoimmune cytopenia medications]] | ||
| + | [[Category:Castleman disease medications]] | ||
[[Category:Erdheim-Chester disease medications]] | [[Category:Erdheim-Chester disease medications]] | ||
| − | [[Category:Hodgkin lymphoma medications]] | + | [[Category:Classical Hodgkin lymphoma medications (historic)]] |
| + | |||
[[Category:FDA approved in 1999]] | [[Category:FDA approved in 1999]] | ||
Revision as of 12:08, 19 August 2023
Mechanism of action
From the NCI Drug Dictionary: A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian target of rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production.
Diseases for which it is used
Diseases for which it was used
Also known as
- Code names: AY-22989, SILA-9268A, SLM, WY-090217
- Generic names: RAPA, rapamycin
- Brand name: Rapamune